Effect of Carotenoids Supplementation on Visual Function in Chinese Subjects Free of Retinal Disease: A Randomized Clinical Trial
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 220
- 主要终点
- Change in contrast sensitivity (CS) at 6 cycles per degree (cpd) over 1 year
研究概览
简要总结
The macula is a pigmented area at the center of the retina, and responsible for the central, high-resolution color vision. Age-related macular degeneration (AMD) is a disease of the macula and is the leading cause of irreversible vision impairment and blindness worldwide. The yellow pigment at the macula is referred to as macular pigment. There is now strong evidence showing that macular pigment (MP), which is composed of the dietary carotenoids lutein (L), meso-zeaxanthin (MZ), and zeaxanthin (Z) is protective against AMD and vision loss. MP is a powerful antioxidant and also filters short-wavelength (blue) light at the macula. The AREDS2 study concluded that supplementation of L and Z is beneficial for patients with non-advanced age-related macular degeneration (AMD). The CREST and other studies had reported that dietary supplementation of these carotenoids could enhance contrast sensitivity among the Caucasian population, whereas little information is known about the effect of dietary supplementation of carotenoids on contrast sensitivity among Chinese. Thus in this study, we aim to investigate whether supplementation of a formulation containing 10 mg L, 10 mg MZ, and 2mg Z on contrast sensitivity in Chinese subjects free of retinal disease. This study is a single-center, double-blinded, placebo-controlled, randomized clinical trial conducted at Zhongshan Ophthalmic Center (ZOC), Sun Yat-sen University, Guangzhou, China. Participants in the intervention group received oral supplementation of 10 mg L, 10 mg MZ, and 2mg Z in a formula base oil suspension as one soft gel capsule in the morning per day. Participants in the control group receive one soft gel capsule of placebo oil per day. The intervention and placebo supplements are identical in external appearance, and the two treatments are therefore indistinguishable from each other. The duration of the study intervention is 12 months, and study visits are conducted at baseline, 3 months, 6 months, and 12 months. The primary outcome measure is the change in contrast sensitivity (CS) at 6 cycles per degree (cpd) over the study course: Y=CS4-CS1, where CS1 is CS at 6 cpd at baseline, CS4 is the CS at 6cpd at the 12-month follow-up. The secondary outcomes of this study include CS at other cpds and at other study visits, best-corrected visual acuity, subjective visual function, and skin carotenoid levels at each study visit.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Supportive Care
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 35 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Chinese subjects
- •Age 35 years or above
- •Monocular BCVA of 6/6 or better
- •No more than +/- 5 diopters spherical equivalence of refraction
- •No previous consumption of supplements containing macular carotenoids (L, Z and/or MZ) within the last 12 months
- •Without severe retinal diseases (eg. retinal detachment, glaucoma, macular hole, idiopathic epiretinal membrane, retinitis pigmentosa, and age-related macular degeneration (assessed by experienced ophthalmologists during ocular examination)
排除标准
- •Unable to provide informed consent
- •With diagnosed diabetes
- •With severe systemic disease which affects physical mobility and successful follow-up
- •Contrast sensitivity at a spatial density of 6 cpd ≤ 1.5 % at baseline in the eye with better visual acuity
- •Subjects who plan to receive cataract surgery within the next year
- •Subjects who are unable to cooperate with the examinations during follow-ups, such as those who suffer from other serious systemic diseases or mental abnormalities
- •History of intraocular surgery (eg. cataract surgery, vitrectomy and retinal laser photocoagulation)
研究组 & 干预措施
Placebo group
Participants in the control group receive one soft gel capsule of placebo oil per day.
干预措施: Placebo (Dietary Supplement)
Carotenoids group
Participants in the intervention group receive oral supplementation of 10 mg L, 10 mg MZ and 2mg Z in a formula base oil suspension as one soft gel capsule in the morning per day. Each capsule contains 22 mg of carotenoids (10+10+2mg), thus each participant in the intervention group will receive a total of 22 mg of carotenoids per day.
干预措施: Carotenoids supplementation (Dietary Supplement)
结局指标
主要结局
Change in contrast sensitivity (CS) at 6 cycles per degree (cpd) over 1 year
时间窗: 1 year
CS at 6 cpd at the 12-month follow-up minus CS at 6 cpd at baseline.
次要结局
- CS at other cpds and at other study visits(1 year)
- Best-corrected visual acuity(1 year)
- Skin carotenoids score(1 year)
- Subjective visual function(1 year)
研究者
Xiaotong Han
Professor
Zhongshan Ophthalmic Center, Sun Yat-sen University
